Business Context and Reporting Period
This Form 8-K Current Report was filed by Barinthus Biotherapeutics Plc. on April 22, 2026. The filing reports a corporate governance event: the appointment of a new Chief Financial Officer (CFO) effective May 1, 2026.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed relates to executive compensation.
- Executive Compensation: The new CFO will receive a fee of $20,000 per month under a Master Services Agreement.
Material Changes
The primary material change is the appointment of Douglas Swirsky as Chief Financial Officer and principal accounting officer, effective May 1, 2026. Mr. Swirsky will provide services through Grand Strand BioAdvisors LLC. This appointment follows his tenure as CFO of MaxCyte, Inc. (2023–2026) and Aavanti Bio, Inc. (2021–2022).
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, market outlook, or discussion of specific business risks. It notes standard indemnification and directors' and officers' liability insurance coverage for the new officer. No unusual items or contingencies were reported.
Investor Verification Checklist
- Verify the effective date of the CFO appointment (May 1, 2026) and the transition plan for the previous principal accounting officer.
- Confirm the terms of the Master Services Agreement with Grand Strand BioAdvisors LLC, specifically regarding the $20,000 monthly fee and any potential equity incentives not detailed in this summary.
- Review the Company's most recent 10-K or 10-Q for current cash runway and liquidity status, as this 8-K does not disclose financial health.